Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytosolic and ER-associated ribosomes share rRNA 2'-O-methylation landscapes across human cell types.

RNA (New York, N.Y.)·2026
Same author

Synthetic circRNAs employ IRES activity for translation in cells and in cell-free translation systems.

bioRxiv : the preprint server for biology·2026
Same author

A tripartite cell-free translation system to study mammalian translation.

Nature protocols·2025
Same author

Pellino 3 E3 ligase promotes starvation-induced autophagy to prevent hepatic steatosis.

Science advances·2025
Same author

Importance of an N-terminal structural switch in the distinction between small RNA-bound and free ARGONAUTE.

Nature structural & molecular biology·2025
Same author

Initiation of a ZAKα-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L.

Cell reports·2024

Related Experiment Video

Updated: May 17, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

MicroRNA and cancer.

Martin D Jansson1, Anders H Lund

  • 1Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark.

Molecular Oncology
|October 30, 2012
PubMed
Summary

MicroRNAs, a type of non-coding RNA, are crucial in cancer development and progression. These molecules are emerging as vital biomarkers for diagnosis and prognosis, and as therapeutic targets in oncology.

Area of Science:

  • Molecular Biology
  • Genomics
  • Oncology

Background:

  • Next-generation sequencing has revealed a vast landscape of non-coding RNA molecules.
  • Non-coding RNAs, particularly microRNAs (miRNAs), are abundant and play critical roles in biological processes and diseases.
  • Human cells host approximately 1400 miRNAs, essential for development, differentiation, growth, and implicated in diseases like cancer.

Purpose of the Study:

  • To review the current understanding of microRNA involvement in cancer.
  • To explore how miRNAs regulate key cancer-related pathways.
  • To highlight the clinical applications of miRNAs in oncology.

Main Methods:

  • Review of existing literature on microRNAs and cancer.
  • Analysis of studies using cell culture and animal models.

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

Related Experiment Videos

Last Updated: May 17, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

  • Examination of miRNA roles in cell cycle control and DNA damage response.

    • Main Results:

    • MicroRNAs are fundamental to normal development and implicated in cancer pathogenesis.
    • Studies demonstrate miRNA regulation of critical cancer pathways, including cell cycle and DNA damage response.
    • MicroRNAs are increasingly utilized as diagnostic and prognostic biomarkers for cancer patient stratification.

    Conclusions:

    • MicroRNAs are key regulators in cancer biology, influencing essential pathways.
    • MicroRNA research provides mechanistic insights into cancer development and progression.
    • MicroRNAs hold significant clinical potential as biomarkers and therapeutic agents in cancer care.